Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen

The aim was to identify mutations in serum cell-free DNA (cfDNA) associated with disease progression on tamoxifen treatment in metastatic breast cancer (MBC). Sera available at start of therapy, during therapy and at disease progression were selected from 10 estrogen receptor (ER)-positive breast cancer patients. DNA from primary tumor and normal tissue and cfDNA from minute amounts of sera were analyzed by targeted next generation sequencing (NGS) of 45 genes (1,242 exons). At disease progression, stop-gain single nucleotide variants (SNVs) for CREBBP (1 patient) and SMAD4 (1 patient) and non-synonymous SNVs for AKAP9 (1 patient), PIK3CA (2 patients) and TP53 (2 patients) were found. Mutations in CREBBP and SMAD4 have only been occasionally reported in breast cancer. All mutations, except for AKAP9, were also present in the primary tumor but not detected in all blood specimens preceding progression. More sensitive detection by deeper re-sequencing and digital PCR confirmed the occurrence of circulating tumor DNA (ctDNA) and these biomarkers in blood specimens.

[1]  Allison Hills,et al.  Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. , 2015, Clinical chemistry.

[2]  J. Carroll,et al.  Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state , 2007, Nature Reviews Cancer.

[3]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[4]  E. Boerwinkle,et al.  dbNSFP v2.0: A Database of Human Non‐synonymous SNVs and Their Functional Predictions and Annotations , 2013, Human mutation.

[5]  S Michiels,et al.  Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[7]  Sarat Chandarlapaty,et al.  Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation , 2016, eLife.

[8]  J. Barrett,et al.  PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer , 2010, Clinical Cancer Research.

[9]  E. Kuipers,et al.  A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory , 2009, Journal of cellular and molecular medicine.

[10]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[11]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[12]  W. Grizzle,et al.  Smad4 as a Transcription Corepressor for Estrogen Receptor α* , 2003, The Journal of Biological Chemistry.

[13]  M. Blagosklonny.  Oncogenic resistance to growth-limiting conditions , 2002, Nature Reviews Cancer.

[14]  R. Pai,et al.  Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer , 2015, Journal of Clinical Pathology.

[15]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  I. Andrulis,et al.  Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario site of the breast cancer family registry (CFR) , 2011, Breast Cancer Research.

[17]  Ravi Vijaya Satya,et al.  Comparison of somatic mutation calling methods in amplicon and whole exome sequence data , 2014, BMC Genomics.

[18]  I. Bièche,et al.  Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types , 2015, Molecular oncology.

[19]  N. Tunariu,et al.  Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration , 2015, Clinical Cancer Research.

[20]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[21]  M. Markman,et al.  Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients , 2015, OncoTargets and therapy.

[22]  N. Girard,et al.  Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002 , 2014, Clinical Cancer Research.

[23]  M. Dowsett,et al.  Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer , 2015, Science Translational Medicine.

[24]  Jaana M. Hartikainen,et al.  Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium , 2014, Human molecular genetics.

[25]  J. Foekens,et al.  c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. , 1992, Cancer research.

[26]  Adrian V. Lee,et al.  Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients , 2015, Clinical Cancer Research.